Product Description
GSK-2256294 is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH. (Sourced from: https://drugs.ncats.io/substance/L33EX3XR0T)
Mechanisms of Action: EPHX Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prediabetes|Brain Infarction|Ischemic Stroke|Vasospasm, Intracranial|Glucose Metabolism Disorders|Cerebral Hemorrhage|Obesity|Intracranial Aneurysm|Subarachnoid Hemorrhage
Phase 1: Chronic Obstructive Pulmonary Disease|Hypoxia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
5R01DK117875 | P2 |
Completed |
Obesity|Prediabetes|Glucose Metabolism Disorders |
2021-11-18 |
|
SUSHI | P2 |
Completed |
Vasospasm, Intracranial|Subarachnoid Hemorrhage|Intracranial Aneurysm|Brain Infarction|Ischemic Stroke|Cerebral Hemorrhage |
2019-04-03 |
|
NCT02262689 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease|Hypoxia |
2015-04-24 |
|
NCT02006537 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2014-05-27 |